CANCER:

Lung Adenocarcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Non Small Cell Lung Cancer (2886)

Lung Non-Squamous Non-Small Cell Cancer (108)

Lung Non-Small Cell Squamous Cancer (88)

Non Small Cell Lung Cancer (2886)

Lung Non-Squamous Non-Small Cell Cancer (108)

Lung Non-Small Cell Squamous Cancer (88)

›

STRN-ALK fusion	Lung Adenocarcinoma	STRN-ALK fusion	Lung Adenocarcinoma	ensartinib Sensitive: C4 – Case Studies Curr Oncol - 1 week (New C4) ensartinib Sensitive : C4 Curr Oncol - 1wk	ensartinib Sensitive: C4 – Case Studies Curr Oncol - 1 week ensartinib Sensitive : C4 Curr Oncol - 1 week - (New C4)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression	Lung Adenocarcinoma	EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression	Lung Adenocarcinoma	pembrolizumab Sensitive: C4 – Case Studies Lung Cancer - 2 weeks (New C4) pembrolizumab Sensitive : C4 Lung Cancer - 2wk	pembrolizumab Sensitive: C4 – Case Studies Lung Cancer - 2 weeks pembrolizumab Sensitive : C4 Lung Cancer - 2 weeks - (New C4)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation	Lung Adenocarcinoma	CD74-NRG1 fusion + EGFR mutation + HER-2 mutation	Lung Adenocarcinoma	afatinib + pyrotinib Sensitive: C4 – Case Studies Thorac Cancer - 2 weeks (New C4) afatinib + pyrotinib Sensitive : C4 Thorac Cancer - 2wk	afatinib + pyrotinib Sensitive: C4 – Case Studies Thorac Cancer - 2 weeks afatinib + pyrotinib Sensitive : C4 Thorac Cancer - 2 weeks - (New C4)
CCDC85A-ALK fusion	Lung Adenocarcinoma	CCDC85A-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies J Cell Mol Med - 2 weeks (New C4) alectinib Sensitive : C4 J Cell Mol Med - 2wk	alectinib Sensitive: C4 – Case Studies J Cell Mol Med - 2 weeks alectinib Sensitive : C4 J Cell Mol Med - 2 weeks - (New C4)
SLC8A1-ALK fusion	Lung Adenocarcinoma	SLC8A1-ALK fusion	Lung Adenocarcinoma	ceritinib Sensitive: C4 – Case Studies Medicine (Baltimore) - 4 weeks (New C4) ceritinib Sensitive : C4 Medicine (Baltimore) - 4wk	ceritinib Sensitive: C4 – Case Studies Medicine (Baltimore) - 4 weeks ceritinib Sensitive : C4 Medicine (Baltimore) - 4 weeks - (New C4)
EGFR exon 21 mutation	Lung Adenocarcinoma	EGFR exon 21 mutation	Lung Adenocarcinoma	dacomitinib Sensitive: C4 – Case Studies Medicine (Baltimore) - 4 weeks (New C4) dacomitinib Sensitive : C4 Medicine (Baltimore) - 4wk	dacomitinib Sensitive: C4 – Case Studies Medicine (Baltimore) - 4 weeks dacomitinib Sensitive : C4 Medicine (Baltimore) - 4 weeks - (New C4)
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1
PD-L1 underexpression	Lung Adenocarcinoma	PD-L1 underexpression	Lung Adenocarcinoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	DP Sensitive: A2 - Guideline DP Sensitive : A2	DP Sensitive: A2 - Guideline DP Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	GC Sensitive: A2 - Guideline GC Sensitive : A2	GC Sensitive: A2 - Guideline GC Sensitive : A2
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2	cisplatin + pemetrexed Sensitive: A2 - Guideline cisplatin + pemetrexed Sensitive : A2
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B	erlotinib Sensitive: B - Late Trials erlotinib Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	erlotinib Resistant: B - Late Trials erlotinib Resistant : B	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma	HER-2 exon 20 insertion + TMB-L + PD-L1 negative	Lung Adenocarcinoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	bevacizumab + erlotinib Sensitive: C1 - Off-label bevacizumab + erlotinib Sensitive : C1	bevacizumab + erlotinib Sensitive: C1 - Off-label bevacizumab + erlotinib Sensitive : C1
PD-L1 expression	Lung Adenocarcinoma	PD-L1 expression	Lung Adenocarcinoma	atezolizumab Sensitive: C1 - Off-label atezolizumab Sensitive : C1	atezolizumab Sensitive: C1 - Off-label atezolizumab Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1	tepotinib Sensitive: C1 - Off-label tepotinib Sensitive : C1
EGFR exon 19 deletion	Lung Adenocarcinoma	EGFR exon 19 deletion	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
BRAF V600E	Lung Adenocarcinoma	BRAF V600E	Lung Adenocarcinoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
ATM mutation	Lung Adenocarcinoma	ATM mutation	Lung Adenocarcinoma	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1	olaparib Sensitive: C1 - Off-label olaparib Sensitive : C1
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1	osimertinib Resistant: C1 - Off-label osimertinib Resistant : C1
EGFR L858R	Lung Adenocarcinoma	EGFR L858R	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	erlotinib Sensitive: C1 - Off-label erlotinib Sensitive : C1	erlotinib Sensitive: C1 - Off-label erlotinib Sensitive : C1
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1	osimertinib Sensitive: C1 - Off-label osimertinib Sensitive : C1
RET fusion	Lung Adenocarcinoma	RET fusion	Lung Adenocarcinoma	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
ALK positive	Lung Adenocarcinoma	ALK positive	Lung Adenocarcinoma	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1	lorlatinib Sensitive: C1 - Off-label lorlatinib Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1	capmatinib Sensitive: C1 - Off-label capmatinib Sensitive : C1
MET exon 14 mutation	Lung Adenocarcinoma	MET exon 14 mutation	Lung Adenocarcinoma	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1	savolitinib Sensitive: C1 - Off-label savolitinib Sensitive : C1
EGFR mutation	Lung Adenocarcinoma	EGFR mutation	Lung Adenocarcinoma	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
ALK rearrangement	Lung Adenocarcinoma	ALK rearrangement	Lung Adenocarcinoma	crizotinib Resistant: C2 – Inclusion Criteria crizotinib Resistant : C2	crizotinib Resistant: C2 – Inclusion Criteria crizotinib Resistant : C2
EGFR T790M	Lung Adenocarcinoma	EGFR T790M	Lung Adenocarcinoma	afatinib Resistant: C2 – Inclusion Criteria afatinib Resistant : C2	afatinib Resistant: C2 – Inclusion Criteria afatinib Resistant : C2

Lung Adenocarcinoma

Associations(508)

Associations
(508)